Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

BACKGROUND: Prospectively designed studies assessing the exposure‐response profile of vedolizumab are lacking. Observational exposure‐response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. AIMS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Aliment Pharmacol Ther
Main Authors: Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Dose Optimisation of Vedolizumab in Ulcerative Colitis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590294/
https://ncbi.nlm.nih.gov/pubmed/30663076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados